NeoGenomics Reports 40% Revenue Growth to $107 Million in the Fourth Quarter
Press Release
Read More
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2019 Earnings Release for February 27, 2020
Press Release
Read More
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
Literature
Read More
PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors
Literature
Read More
Phenotypic Characterization of the Immune Landscape in the Bone Marrow of Patients with Acute Myeloid Leukemia (AML) Using MultiOmyx™ Hyperplexed Immunofluorescence Assay
Literature
Read More